The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol โABBVโ.
According to AbbVie's latest financial reports the company's current EPS (TTM) is NZ$2.34. In 2024 the company made an earnings per share (EPS) of NZ$4.19 a decrease over its 2023 EPS that were of NZ$4.76.